Cargando…

10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach

ABSTRACT IMPACT: Understanding gene expression changes after viral vaccination and booster may help predict vaccine efficacy. OBJECTIVES/GOALS: Utilize a systems biology approach to identify gene expression changes after administration of Zaire Ebola virus glycoprotein expressed in a Chimp Adeno3 ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Olivia, Song, Yang, Daugherty, Sean, Sztein, Rezwan Wahidrcelo B., Fraser, Claire M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827761/
http://dx.doi.org/10.1017/cts.2021.626
_version_ 1784647705811746816
author Martin, Olivia
Song, Yang
Daugherty, Sean
Sztein, Rezwan Wahidrcelo B.
Fraser, Claire M.
author_facet Martin, Olivia
Song, Yang
Daugherty, Sean
Sztein, Rezwan Wahidrcelo B.
Fraser, Claire M.
author_sort Martin, Olivia
collection PubMed
description ABSTRACT IMPACT: Understanding gene expression changes after viral vaccination and booster may help predict vaccine efficacy. OBJECTIVES/GOALS: Utilize a systems biology approach to identify gene expression changes after administration of Zaire Ebola virus glycoprotein expressed in a Chimp Adeno3 vector (ChAd3-EBOZ) and either boosted ˜7 weeks later with modified vaccinia Ankara MVA expressing Zaire and Marburg GPs plus Tai forest NP (MVA-BN ®Filo) or given saline (placebo). METHODS/STUDY POPULATION: As part of the phase 1b, open-label vaccination trial of ChAd3-EBO-Z in Mali, West Africa, peripheral blood mononuclear cells were isolated from eight volunteers for whole genome transcriptomics analysis. Four subjects received the MVA-BN ®-Filo booster and four received saline. Samples were taken prior to receipt of the booster or placebo, as well as 1, 7, and 14 days afterwards. Significant differentially expressed genes were identified using RNA-seq between baseline and post-MVA-BN ®Filo. Functional enrichment analysis against the GO Ontology Database and the Immune Signatures C7 collection of MSigDB (ImmuneSigDB) was performed. These differentially expressed genes were also examined for associations with Ebola antibody titers and cell-mediated immune responses. RESULTS/ANTICIPATED RESULTS: The majority of gene expression changes occurred on day 1 post-MVA-BN ®-Filo administration. 870 genes had significantly different expression when day 1 samples were compared to pre-booster baseline (791 upregulated/79 downregulated). Those upregulated genes are mainly involved type I interferon and regulation of viral life cycle pathways. The downregulated genes are involved in regulation of cellular defense response, lymphocyte mediated immunity. Comparing to the C7 Immune Signatures collection datasets, we identified more than 100 upregulated genes from 6 studies of yellow fever vaccination that were also significantly upregulated in our study. The top enriched ontological pathway of those genes is cellular response to type I Interferon. DISCUSSION/SIGNIFICANCE OF FINDINGS: The use of a systems biology approach to compare gene expression changes among vaccine studies utilizing whole genome transcriptomics data allows the identification of genes involved in the immune response to vaccination and might aid in predicting vaccine efficacy.
format Online
Article
Text
id pubmed-8827761
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-88277612022-02-28 10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach Martin, Olivia Song, Yang Daugherty, Sean Sztein, Rezwan Wahidrcelo B. Fraser, Claire M. J Clin Transl Sci Mechanistic Basic to Clinical ABSTRACT IMPACT: Understanding gene expression changes after viral vaccination and booster may help predict vaccine efficacy. OBJECTIVES/GOALS: Utilize a systems biology approach to identify gene expression changes after administration of Zaire Ebola virus glycoprotein expressed in a Chimp Adeno3 vector (ChAd3-EBOZ) and either boosted ˜7 weeks later with modified vaccinia Ankara MVA expressing Zaire and Marburg GPs plus Tai forest NP (MVA-BN ®Filo) or given saline (placebo). METHODS/STUDY POPULATION: As part of the phase 1b, open-label vaccination trial of ChAd3-EBO-Z in Mali, West Africa, peripheral blood mononuclear cells were isolated from eight volunteers for whole genome transcriptomics analysis. Four subjects received the MVA-BN ®-Filo booster and four received saline. Samples were taken prior to receipt of the booster or placebo, as well as 1, 7, and 14 days afterwards. Significant differentially expressed genes were identified using RNA-seq between baseline and post-MVA-BN ®Filo. Functional enrichment analysis against the GO Ontology Database and the Immune Signatures C7 collection of MSigDB (ImmuneSigDB) was performed. These differentially expressed genes were also examined for associations with Ebola antibody titers and cell-mediated immune responses. RESULTS/ANTICIPATED RESULTS: The majority of gene expression changes occurred on day 1 post-MVA-BN ®-Filo administration. 870 genes had significantly different expression when day 1 samples were compared to pre-booster baseline (791 upregulated/79 downregulated). Those upregulated genes are mainly involved type I interferon and regulation of viral life cycle pathways. The downregulated genes are involved in regulation of cellular defense response, lymphocyte mediated immunity. Comparing to the C7 Immune Signatures collection datasets, we identified more than 100 upregulated genes from 6 studies of yellow fever vaccination that were also significantly upregulated in our study. The top enriched ontological pathway of those genes is cellular response to type I Interferon. DISCUSSION/SIGNIFICANCE OF FINDINGS: The use of a systems biology approach to compare gene expression changes among vaccine studies utilizing whole genome transcriptomics data allows the identification of genes involved in the immune response to vaccination and might aid in predicting vaccine efficacy. Cambridge University Press 2021-03-31 /pmc/articles/PMC8827761/ http://dx.doi.org/10.1017/cts.2021.626 Text en © The Association for Clinical and Translational Science 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mechanistic Basic to Clinical
Martin, Olivia
Song, Yang
Daugherty, Sean
Sztein, Rezwan Wahidrcelo B.
Fraser, Claire M.
10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach
title 10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach
title_full 10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach
title_fullStr 10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach
title_full_unstemmed 10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach
title_short 10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach
title_sort 10061 assessing immunogenicity of an ebola vaccine in humans using a systems biology approach
topic Mechanistic Basic to Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827761/
http://dx.doi.org/10.1017/cts.2021.626
work_keys_str_mv AT martinolivia 10061assessingimmunogenicityofanebolavaccineinhumansusingasystemsbiologyapproach
AT songyang 10061assessingimmunogenicityofanebolavaccineinhumansusingasystemsbiologyapproach
AT daughertysean 10061assessingimmunogenicityofanebolavaccineinhumansusingasystemsbiologyapproach
AT szteinrezwanwahidrcelob 10061assessingimmunogenicityofanebolavaccineinhumansusingasystemsbiologyapproach
AT fraserclairem 10061assessingimmunogenicityofanebolavaccineinhumansusingasystemsbiologyapproach